title: [Combination therapy of antibiotics and intravenous immunoglobulin].
abstract: A large scale multicenter randomized controlled study was conducted to evaluate the efficacy of intravenous immunoglobulin in combination with IPM/CS and AMK in 504 evaluable patients who did not respond by 3 day therapy with beta-lactum and aminoglucoside. Immunoglobulin 5 g was administered 3 days to the patients allocated to immunoglobulin group. A completely automatic computer evaluation was performed according to the criteria determined by the committee. The response rate was 61.5% in immunoglobulin group and 47.3% in control group(p < 0.001). Intravenous immunoglobulin is considered effective for severe infection when used as combination therapy with antibiotics.
authors: Osaka Medical Center for Cancer and Cardiovascular Diseases.
authors: T
authors: T
authors: Masaoka
mesh_terms: D000583:Amikacin / Q000008:administration & dosage*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001424:Bacterial Infections / Q000188:drug therapy; D015377:Cilastatin / Q000008:administration & dosage*; D004359:Drug Therapy, Combination / Q000008:administration & dosage*; D006801:Humans; D015378:Imipenem / Q000008:administration & dosage*; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D015337:Multicenter Studies as Topic; D011480:Protease Inhibitors / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic; D013845:Thienamycins / Q000008:administration & dosage*
chemical_list: D000900:Anti-Bacterial Agents; D016756:Immunoglobulins, Intravenous; D011480:Protease Inhibitors; D013845:Thienamycins; D015377:Cilastatin; D015378:Imipenem; D000583:Amikacin